The Department of Health and Human Services is aware of 20 pharmaceutical products made or with a critical active ingredient solely sourced in China, but to date is not aware of any expected shortages, HHS Secretary Alex Azar told House appropriators today. He said the agency knows of two pharmaceutical makers in Hubei Province, the epicenter of the novel coronavirus (COVID-19) outbreak, but they have a large stockpile supply of advance production.

For the first time since the outbreak started, more new cases are being reported outside China than from China, the World Health Organization said today. While China continues to have the most cases overall, there are now confirmed COVID-19 cases on every continent except Antarctica, totaling more than 81,000 in 37 countries.

The Centers for Disease Control and Prevention continues to update resources, including interim guidance for businesses and employers to plan and respond to COVID-19.

For the latest information and resources, visit AHA’s coronavirus webpage.

Related News Articles

Headline
The AHA's Living Learning Network is partnering with the Centers for Disease Control and Prevention to launch the Sepsis Champions Leadership Series. These…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Centers for Disease Control and Prevention today released an advisory recommending clinicians expedite subtyping of type A influenza samples from…
Headline
The San Francisco Department of Public Health Jan. 10 announced a presumptive positive case of H5N1 bird flu in a child after they experienced symptoms of…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Louisiana Department of Health yesterday announced that a patient hospitalized last month for H5N1 bird flu has died, becoming the first U.S. death from…